Colossal Biosciences, the de-extinction company known for its ambitious work in genetic science, is reportedly discussing a fresh funding round that could value the startup between $20 billion and $30 billion. The company was last valued at $10.2 billion.
According to the report, the five-year-old firm has begun generating revenue over the past year, adding a commercial layer to its long-term research vision. Founder and CEO Ben Lamm has previously outlined multiple business lines, including conservation technology and spin-off ventures.
Those spinouts include Breaking, which focuses on plastic breakdown, Form Bio, a computational biology platform, and Astromech, an AI-powered modeling company centered on biology and life sciences. Colossal has also discussed artificial womb technology as a possible future platform with broader fertility applications.
The company's wider roadmap includes potential biodiversity credit revenue if it succeeds in restoring extinct species such as the woolly mammoth and dodo bird to suitable habitats. As deep-tech investment continues to accelerate, Colossal's next financing move could become a notable signal for the future of synthetic biology and conservation innovation.
